Hookipa Pharma to present HB-700 dataset at RAS-Targeted Drug Development Summit

HOOKIPA Pharma announced that the Company will present preclinical data related to the HB-700 program for the treatment of KRAS mutated cancers at the 6th Annual RAS-Targeted Drug Development Summit being held in Boston, Massachusetts from September 24-26, 2024. “HOOKIPA is very pleased to present a comprehensive preclinical proof-of-concept dataset related to HB-700, for the potential treatment of KRAS mutated cancers. KRAS mutations are most frequently found in pancreatic, colorectal and lung cancers. While a number of KRAS programs are focused on a single mutation, our program is uniquely suited to target the most prevalent KRAS mutations of these cancers in a single therapy,” said Mark Winderlich, PhD, Chief Research & Development Officer. “HOOKIPA’s approach could enable HB-700 to be a widely used, multi-KRAS therapy. The preclinical dataset has demonstrated safety, induction of target-specific CD8+ T-cells, and target cell killing in several different animal and translational models. With IND clearance, received from the FDA in Q2 2024, HB-700 is a Phase 1 ready asset.”